Previous close | 0.2000 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2024-12-20 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
SAN FRANCISCO, May 22, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will highlig
SAN FRANCISCO, May 21, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data
Shareholders in Vir Biotechnology, Inc. ( NASDAQ:VIR ) may be thrilled to learn that the analysts have just delivered a...